<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Risk factors for the development of a new (secondary) <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> after marrow transplantation are still incompletely defined </plain></SENT>
<SENT sid="1" pm="."><plain>In the present study, we analyzed results in 700 patients with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> treated with allogeneic marrow transplantation at the Fred Hutchinson <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Research Center in Seattle, WA, or at the HÃ´pital St Louis in Paris, France </plain></SENT>
<SENT sid="2" pm="."><plain>Twenty-three patients developed a <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> 1.4 to 221 months (median, 91 months) after transplantation for a Kaplan-Meier estimate of 14% (95% confidence interval, 4% to 24%) at 20 years </plain></SENT>
<SENT sid="3" pm="."><plain>Five cases were lymphoid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> (two <z:hpo ids='HP_0006721'>acute lymphoblastic leukemias</z:hpo> and three <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo>) occurring 1.4 to 14.6 months (median, 3 months) posttransplant, and 18 were <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> (17 squamous cell and one mucoepidermoid <z:mp ids='MP_0002038'>carcinoma</z:mp>) presenting 30 to 221 months (median, 99 months) posttransplant </plain></SENT>
<SENT sid="4" pm="."><plain>Thus, the hazard for lymphoid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> declined rapidly posttransplant, while the hazard for <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> increased progressively with time posttransplant </plain></SENT>
<SENT sid="5" pm="."><plain>Risk factors for <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> identified in univariable analysis included the underlying diagnosis of Fanconi <z:hpo ids='HP_0001903'>anemia</z:hpo> (P = .0002), <z:chebi fb="2" ids="2948">azathioprine</z:chebi> therapy for <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) (P &lt; .0001), irradiation (total body or thoracoabdominal) as part of the conditioning regimen (P = .0002), <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD (P = .0099), <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD (P = .0135), and male sex (P = .0499) </plain></SENT>
<SENT sid="6" pm="."><plain>In multivariable, stepwise proportional hazards models, <z:chebi fb="2" ids="2948">azathioprine</z:chebi> therapy (P &lt; .0001) and the diagnosis of Fanconi <z:hpo ids='HP_0001903'>anemia</z:hpo> (P &lt; .0001) were significant factors for <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="7" pm="."><plain>Irradiation was a significant factor (P = .004) only if the time-dependent variable <z:chebi fb="2" ids="2948">azathioprine</z:chebi> was not included in the analysis </plain></SENT>
<SENT sid="8" pm="."><plain>If only non-Fanconi patients were considered, <z:chebi fb="2" ids="2948">azathioprine</z:chebi> (P = .0043), age (P = .025), and irradiation (P = .042) were significant factors </plain></SENT>
<SENT sid="9" pm="."><plain>Results in patients with Fanconi <z:hpo ids='HP_0001903'>anemia</z:hpo> and <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> other than <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> were not subjected to an analysis because of the small number of events </plain></SENT>
<SENT sid="10" pm="."><plain>It is of note, however, that no case of <z:hpo ids='HP_0005547'>myeloproliferative disorder</z:hpo> was observed </plain></SENT>
<SENT sid="11" pm="."><plain>In summary, the highest risk of developing a <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumor</z:e> was associated with the diagnosis of Fanconi <z:hpo ids='HP_0001903'>anemia</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>Better prevention of GVHD or omission of <z:chebi fb="2" ids="2948">azathioprine</z:chebi> as GVHD therapy (or both) may reduce the risk of late <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> development </plain></SENT>
<SENT sid="13" pm="."><plain>Similarly, nonirradiation conditioning regimens may reduce the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> risk, at least in patients without Fanconi <z:hpo ids='HP_0001903'>anemia</z:hpo> </plain></SENT>
<SENT sid="14" pm="."><plain>Interactions between potential risk factors are complex, and further observation and additional analyses will be of interest </plain></SENT>
</text></document>